Stemcentrx Report issue

For profit Phase 1 Phase 2
Founded: South San Francisco CA United States (2008)
Status: Acquired by AbbVie (2016)

Organization Overview

First Clinical Trial
2013
NCT01901653
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

rovalpituzumab tesirine (5 trials)

Drugs in Phase 1 Trials (4)

cisplatin (platinol) (1 trial)

etoposide (vepesid) (1 trial)

sc002 (1 trial)

sc-003 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 1)

Glioblastoma (Phase 2)

Lung Neoplasms (Phase 2)

Melanoma (Phase 2)

Ovarian Neoplasms (Phase 1)

Small Cell Lung Carcinoma (Phase 2)

Thyroid Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 5